Antigen Discovery

While we are currently focusing our internal efforts on the development of personalized cancer vaccines, we have demonstrated that our proprietary ATLASTM antigen identification platform can be used across a broad range of disease applications and are seeking partners to realize the full potential of ATLAS in the following antigen discovery areas:

  • Tumor-associated antigen (TAA) Programs:
    • Profiling T cell responses to known and novel TAAs to enable the development of diagnostic tools, prognostic/companion diagnostic tools for infectious diseases and cancer
    • TAA identification for development of cancer vaccines
  • Epstein-Barr Virus (EBV)-related cancers:
    • Genocea has demonstrated the feasibility of utilizing the ATLAS platform to characterize the T cell responses to EBV in a pilot screening campaign. Results of these efforts were presented in May 2017 at the AAI IMMUNOLOGY conference.
    • EBV is a human herpesvirus that infects about 95% of the population. More recently, the virus has been associated with several types of cancer, notably Burkitt’s and Hodgkin lymphomas, gastric and nasopharyngeal carcinoma, and post-transplant lymphoproliferative disease. Thus, understanding and exploiting the immune responses to the virus provides a unique opportunity to create novel vaccine candidates that could impact both infectious disease and cancer.

Current Partnerships

  • US Oncology Research: In December 2016, we announced a collaboration with US Oncology Research, one of the USA's largest research programs specializing in oncology clinical trials, to screen the T cell responses of cancer patients with solid tumors who will be treated with checkpoint inhibitors against the complete repertoire of patient-specific putative cancer neoantigens. The objective of the collaboration is to use ATLAS to further Genocea's expertise in identifying signatures of T cell responses in cancer patients and to discover new T cell cancer vaccine antigens.

 

Contact us to explore ways we can work together on these important programs